URGN (UroGen Pharma Ltd.) Forward P/E Multiple

Official company branding of UroGen Pharma (URGN)

UroGen Pharma Ltd. (URGN) aims for leadership in uro-oncology through the implementation of the RTGel platform and the expanded application of Jelmyto. By comparing the company's expected P/E ratio on GURU.Markets, we see that the value 11.30 describes the current level of market expectations. Strict pharmaceutical delivery ensures drug integrity, while increasing availability in clinics triggers operating leverage, effectively boosting the business's bottom-line margins.

UroGen Pharma - URGN Forward P/E Multiple (period 07/04/2022 - 11/17/2026)

Summary analytical data breakdowns for UroGen Pharma (URGN)

- current price and projected stock value:
Comprehensive company analysis:URGN UroGen
Brand item of urogen.com

The forward P/E reflects the ratio of the current market share price to the expected annual net income. An increase in this metric signals an overvaluation of the asset, while a decrease indicates potential undervaluation. By analyzing the projected P/E multiple of a company, an investor assesses whether market optimism is justified. This is critical for UroGen Pharma Ltd. (URGN), as earnings depend on insurance reimbursements for hydrogel therapy. The trend of this indicator confirms the stability of the commercialization of oncology drugs.

Direct competitors

Forward P/E Multiple ONC|HALO (Halozyme Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (revmed.com)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|BCAX - Forward P/E Multiple|Personalis Corp (PSNL) - Future Price to Earnings|Erasca Corp - Future Price to Earnings Multiple|DCTH (Delcath Systems Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Y-mAbs Therapeutics, Inc. YMAB|Forward P/E Multiple AURA|Projected Price to Earnings Candel Therapeutics, Inc. CADL|Forward P/E Multiple ARAY (Accuray, Inc.)|SELLAS Life Sciences - Future Price to Earnings|ACTU: Projected Price to Earnings|Citius Oncology, Inc. - Market Cap to Future Earnings Ratio|HURA (TuHURA Biosciences) - Projected Price to Earnings|TARA: Market Cap to Future Earnings Ratio|Projected Price to Earnings FATE|WHWK: Future Price to Earnings Multiple|Projected Price to Earnings TCRX (TScan Therapeutics Inc)|Market Cap to Projected Earnings Champions Oncology Inc|Forward P/E Multiple XBIT (XBiotech Inc.)|Future Price to Earnings Multiple CVM|OS Therapies Inc. - Forward P/E Multiple|RADX - Forward P/E Multiple|ARTV: Forward P/E Multiple|ANL: Market Cap to Future Earnings Ratio|Projected Price to Earnings VERU|TPST: Future Price to Earnings Multiple|Future Price to Earnings xiliotx.com (XLO)|Renovaro - Price to Future Earnings Ratio|Future Price to Earnings Mural Oncology MURA|KAPA - Projected Price to Earnings|OKUR - Future Price to Earnings|GDTC - Forward P/E Multiple|Curis, Inc. (CRIS) - Future Price to Earnings|Projected Price to Earnings Apollomics, Inc.|Projected Price to Earnings THAR|Price to Future Earnings Ratio ADVB (Advanced Biomed)|Projected Price to Earnings GNPX (Genprex, Inc)|CLDI: Price to Expected Earnings Ratio|Future Price to Earnings sunshinebiopharma.com SBFM|XBIO - Projected Price to Earnings|SLRX: Projected Price to Earnings|Purple Biotech - Market Cap to Future Earnings Ratio|American Oncology Network (AONC) - Future Price to Earnings|Price to Future Earnings Ratio BGNE|Projected Price to Earnings CKPT|Future Price to Earnings ELEV|Forward P/E Multiple ICAD|Forward P/E Multiple Ikena Oncology Inc. (IKNA)|Forward P/E Multiple NTBL (Notable Labs Ltd)|Market Cap to Projected Earnings Viracta Therapeutics (VIRX)|MOR: Projected Price to Earnings|NAYA (NAYA Bio) - Price to Future Earnings Ratio|AAPGV: Forward P/E Multiple